http://www.pharmaceuticalmarkets.com/ Report dipesh_hirani@byteart.com (Dipesh Hirani) http://cyber.law.harvard.edu/rss/rss.html http://www.pharmaceuticalmarkets.com/graphics/logo.gifhttp://www.pharmaceuticalmarkets.com/ 60 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=269 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=269 The pharmaceutical industry is one of the fastest growing sectors in Indian economy. Visiongain predicts that market for pharmaceuticals in India has strong potential for increased growth from 2008 right through to 2023. The industry's leading Indian Pharma report contains unique market-based research, including detailed interviews with key opinion leaders based in India and abroad. (pharmaceuticalmarkets) Fri, 16 May 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=272 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=272 In 2006, Pfizer's Lipitor (atorvastatin) generated global revenues of $13.6bn, making it the best selling drug in pharmaceutical history. The blockbuster medicine has single-handedly driven the overall revenue margins of the cardiovascular segment, as this area continues to dominate the pharmaceutical market. (pharmaceuticalmarkets) Tue, 06 May 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=274 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=274 The market penetration for insomnia drugs has not reached saturation point. Opportunities remain. But with the introduction of several new products the market is set to see changes, but expansion. This expansion is based on increased general awareness physicians better comprehension of the significance of this disease and the positive role that a sleep medication prescription plays. (pharmaceuticalmarkets) Tue, 25 Mar 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=275 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=275 This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. (pharmaceuticalmarkets) Wed, 19 Mar 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=276 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=276 The generic industry is a fast evolving market; with significant lucrative opportunities. The generic market is structurally set to experience high growth potential. That wave is partly driven by cost-containment in several national healthcare sectors and partly by the need for governments to promote the use of generic products over high-priced originator products without compromising quality. (pharmaceuticalmarkets) Wed, 27 Feb 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=278 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=278 The total antipsychotics market revenue in 2006 was $18.1bn. Visiongain predicts that total revenues in the antipsychotics market will peak to $18.6bn by 2007. But what will it be in 2012? (pharmaceuticalmarkets) Tue, 19 Feb 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=280 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=280 This brand new report examines the forthcoming prospects for respiratory drugs over the next 5 year. With in-depth sales forecasts for leading pharmaceutical products, the report has been produced to inform you of future developments and strategies. The respiratory market generated revenues of $30503m in 2006, but what will it be in 2013,? Which year will see it reach its peak? (pharmaceuticalmarkets) Mon, 11 Feb 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=282 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=282 Visiongain predict that the current phase I to IV clinical testing process will eventually be selectively or wholly replaced by a system known as "in-life testing" or "live-licensing". Those proposals involve cumulative testing of the drug throughout its lifecycle. The industry would continually test drugs with smaller, more focused clinical trials. If a trial shows efficacy and safety, a live license would be given, allowing the company to market the drug in a limited manner. (pharmaceuticalmarkets) Thu, 17 Jan 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=283 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=283 Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease. (pharmaceuticalmarkets) Tue, 08 Jan 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=303 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=303 Technological solutions are playing an increasingly important role in both clinical practice and pharmaceutical R&D - increasing safety, speeding up clinical development and facilitating regulatory acceptance. Furthermore, current developments in diagnostics - especially molecular diagnostics - are paving the way towards the long-held goal of personalised medicine, to the benefit of patients, companies and healthcare providers. (pharmaceuticalmarkets) Wed, 25 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=306 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=306 This brand new report examines the prospects for the growth of pharmaceutical revenues in China. Visiongain predicts that total pharmaceutical revenues in China will increase from approximately $12bn in 2007 to over $30bn in 2013. This is a considerable increase, one that will represent a near tripling of total sales over six years. Strong growth will continue well beyond that period, as this report shows and explains. (pharmaceuticalmarkets) Wed, 16 Apr 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=308 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=308 In 2007, Amgen Inc - the world's largest biotechnology company - achieved total sales of $14.7bn, despite a turbulent year marked by regulatory, pricing and reimbursement issues. Amgen has now firmly established itself as a Top-20 international pharmaceutical company. According to sales data for 2007, Amgen is also ranked as the 11th largest pharmaceutical company worldwide based on total sales value. This is a remarkable achievment for a biotechnology company founded in 1980. (pharmaceuticalmarkets) Thu, 19 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=315 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=315 The global clinical trials business is worth an estimated $50bn in 2008, with a growth of rate of 10%. The market will show considerable growth in the future, as this visiongain report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the nature of clinical trials has changed considerably. (pharmaceuticalmarkets) Thu, 10 Jul 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=319 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=319 This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies therapeutics is thriving and growing at a double-digit rate. (pharmaceuticalmarkets) Fri, 25 Jul 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=320 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=320 The major problem facing the Wholesale & Distribution industry is its low profit margin which is in the region of only 1-2%. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. (pharmaceuticalmarkets) Mon, 02 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=322 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=322 Visiongain have the pleasure of announcing the latest edition of their industry leading report - The World OTC Pharmaceutical Market, 2008-2023. This edition updates the world OTC market at present and predicts its sales revenues and trends from 2008-2023, including drivers and restraints on the market. (pharmaceuticalmarkets) Wed, 18 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=323 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=323 The UK government have told kidney cancer patients that new drugs cannot be offered on the National Health Service. Roche's Avastin, Bayer's Nexavar, Pfizer's Sutent and Wyeth's Torisel were not cost-effective. The drugs -- known generically as bevacizumab, sorafenib, sunitinib and temsirolimus -- should therefore not be a treatment option for advanced and/or metastatic kidney cancer, NICE said. (pharmaceuticalmarkets) Thu, 10 Jul 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=326 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=326 Pfizer is the world's largest and most profitable pharmaceutical company. Its pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. (pharmaceuticalmarkets) Fri, 08 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=330 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=330 The revenue for world contract manufacturing business in 2007 was approximately $30bn, with a growth rate of 6% from 2006. The technical expertise and cost savings offered by contract manufacturing organisations (CMOs) make them increasingly essential to you and your organisation. (pharmaceuticalmarkets) Fri, 15 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=331 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=331 In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured? (pharmaceuticalmarkets) Fri, 15 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=333 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=333 The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970s. (pharmaceuticalmarkets) Tue, 26 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=336 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=336 The key growth driver for vaccines is their cost-effectiveness in combating disease. This situation will encourage greater use of vaccines by governments and private healthcare providers. New disease targets that could be mitigated through vaccination, including high profile (and potentially profitable) targets such as cancer. (pharmaceuticalmarkets) Mon, 01 Sep 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=338 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=338 Investors are turning their attention to antiviral drug discovery because there is a renewed recognition of the promising opportunities in this $20bn market. Twenty years from the inception of focused antiviral drug research, there are 8 blockbuster drugs currently on the market. (pharmaceuticalmarkets) Wed, 10 Sep 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=340 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=340 This visiongain report provides a detailed analysis of the market for women's reproductive health pharmaceutical products. The report discusses current and future products and market climates for the following areas: - Hormonal contraceptive use - Use of hormone replacement therapy (HRT) for menopause - Infertility therapeutics. (pharmaceuticalmarkets) Tue, 30 Sep 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=342 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=342 Last year, the Japanese pharmaceutical market was the second largest in the world, with a value of $58.5bn. However, Japan's market has experienced growth at a much lower rate than the other major pharmaceutical markets. It is at a key stage in its development. You need to take notice of these changes. (pharmaceuticalmarkets) Fri, 10 Oct 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=344 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=344 The gastrointestinal (GI) disorders market has been one of the largest and most profitable therapeutic areas in the world pharmaceutical industry. However. the market is now mature, with well-established treatments now nearing the end of their patent life. So can you and your company continue to benefit from this market? (pharmaceuticalmarkets) Thu, 30 Oct 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=346 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=346 The global addiction market is significantly undervalued. The world's population has a large unmet need for addiction therapy drugs. Are you ready for the opportunities this presents? The brand new report, The Global Anti-Addiction Market, 2008-2023, provides an in-depth analysis of the current state of the market for addiction therapy drugs, from the present looking forward. (pharmaceuticalmarkets) Wed, 05 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=351 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=351 The global pain market generated total sales of $34bn in 2007 - but what will the figures be in the next 5 and 10 years? This report tells you. (pharmaceuticalmarkets) Thu, 13 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=352 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=352 In 2007, blood diseases cost the US's economy $114bn. In 2004, a reported 232,000 deaths in the US were due to anaemia, myeloproliferative and myelodysplastic disorders, bleeding disorders, white blood cell disorders and thrombosis collectively. (pharmaceuticalmarkets) Mon, 14 Apr 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=353 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=353 The generics market remains a major growth area in the global healthcare market. That growth has been partly driven by cost-containment in several national healthcare sectors, with governments seeking to promote the use of generic products over higher-priced originator products. The global generic pharmaceuticals market was worth over $100bn in 2007, with market growth noticeably higher that that of the overall pharmaceutical market. (pharmaceuticalmarkets) Mon, 24 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=355 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=355 The biotechnology industry is a major growth area in the global healthcare market, one upon which many companies are placing their hopes. Due to developments in monoclonal antibodies, genomics and proteomics - amongst others - the biotechnology market has experienced great expansion since its emergence during the 1970's. (pharmaceuticalmarkets) Thu, 04 Dec 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1028 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1028 This new market analysis by visiongain is to examine the current and future prospects for the world dermatological market. The world dermatological market generated total sales revenues of over $18bn in 2007. Visiongain predicts that this market area will expand further, increasing its total revenues significantly based on expansion of the market for modern drugs to treat skin disorders in developing countries, most notably China, India and Brazil. (pharmaceuticalmarkets) Thu, 08 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1029 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1029 The global market for ophthalmic pharmaceuticals is a large and profitable segment of the healthcare market, with ophthalmic sales of over $10bn in 2007. The recent therapeutic and commercial success of Lucentis has increased the number of blockbuster ophthalmic drugs and highlighted the lucrative commercial rewards on offer in this sector. Which will be the blockbusters of the future? (visiongain) Thu, 15 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1030 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1030 Smoking is the leading cause of preventable death in the world. The effects of smoking represent a global pandemic of enormous proportions. Currently-marketed smoking cessation aids typically lack high levels of efficacy in practice and are associated with marked side-effects. There are clear market opportunities for novel, more-efficacious and safer smoking cessation agents, in both prescription and OTC forms. (pharmaceuticalmarkets) Tue, 03 Feb 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1033 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1033 The data of this report partly comes from such authorities as State Statistics Bureau, Ministry of Health and industry associations, and our research center which has various first-hand materials through field research and interview with specialists. The report has analyzed China's biopharmaceutical industry in terms of production and sales, import and export, sub-sectors and development trend. It is a valuable reference for you to understand the current situation of China's biopharmaceutical industry and its development trend. (Bruce.Chang) Wed, 05 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1034 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1034 This report analyzes China blood product market from various aspects such as production, supply and demand which makes investors understand the status of the market, the competition situation, as well as the profiles of the manufacturers. The report helps investors find investment opportunities, avoid investment risks and make right decisions. (Bruce.Chang) Sat, 08 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1035 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1035 In 2008, the market size of Chinese animal vaccine is about 3 billion Yuan (0.43 billion US Dollars), increased by 30% in 2007, and will still keep a fast growth in years. (Jimmy.Wong) Mon, 02 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1036 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1036 In 2008, the market size of China's biopharmaceutical industry was about 70 billion Yuan (about 10 billion US Dollars), whose growth rate passed the whole market size of China's medicine market and also above three sub-sectors including chemical medicine materials, chemical medicine dose and traditional Chinese prepared medicines. Under the circumstances of global economic depression, however, China's biopharmaceutical industry shows a good momentum of development. (Bruce.Chang) Mon, 02 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1037 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1037 Although the largest medical instrument markets are America, Europe and Japan now in the world, China is generally acknowledged the hugest potential market. In the developed countries, the output values between medical instruments and manufacture are 1: 19. It is only 1: 5 in China. There is a huge potential for medical instrument market in China. (Bruce.Chang) Mon, 16 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1038 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1038 Foot-and-mouth disease was the first animal virus people recognized. People had struggled with it for more than one hundred years. Besides several countries with natural quarantine conditions, foot-and-mouth disease still out broke and spread in many countries. Since the reform and open up, the animal husbandry has developed fast in China. However, because of the backward cultivation in the rural, the unsoundness of animal epidemic prevention systems and the outbreaks of foot-and-mouth disease in the neighboring countries, the foot-and-mouth disease greatly affected Chinese animal husbandry. (Jimmy.Wong) Mon, 23 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1039 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1039 The blood product industry is stemmed and developed from the blood transfusion, belonging to the conceptual category of biological products. The blood products, extracted the plasma proteins and factor concentrates from the blood, are the precious human biological products with irreplaceable prevention functions to many diseases. So far, there is no qualified man-made substitute. (Bruce.Chang) Mon, 23 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1040 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1040 The traditional Chinese medicine industry researched in this report concludes two parts: the traditional Chinese medicine pill processing industry and the proprietary Chinese medicine manufacture. In 2008, the scale of the traditional Chinese medicine market was about 26 billion USD and the yields totaled 1.2 million tons. The upstream industry of the traditional Chinese medicine industry concludes the traditional Chinese medicine farming and the downstream industry of the medicine circulation, residential health and insurance etc. (Rati. Lee) Tue, 07 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1041 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1041 The development of Chinese laboratory medicine fell far behind the world’s advanced level for a long time. In the 1970s, China still continued to use the methods in the 1950s, namely, the various necessary diagnostics reagents were self-prepared by the technicians. In the 1970s, China began to introduce some foreign advanced equipments and technologies. Since the 1980s, Chinese clinical diagnostic reagent industry had quickly step into the industrialization process with the introduction of the foreign capitals. (Bruce.Chang) Tue, 28 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1042 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1042 The contract research market grew by 12% last year and performed far better than the pharma market that it serves - but this year growth has stopped and the market cap of publicly quoted CROs has fallen sharply. Why has growth stopped, and why have share prices fallen in a market that was booming? This review provides a complete picture of the market, looks at trends and developments and explains why they have happened and how they will affect the future of the market. (Dr. Graham Hughes) Wed, 24 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1043 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1043 A definitive report on the current status and future prospects of Central Clinical Pathology Laboratories, Central ECG Analysis Laboratories and Central Bio-imaging Laboratories. The Central and Core Laboratories market is now worth more than $1.5 billion a year and is vital to the successful development of new drugs. It is a truly global business dominated by major players. (pharmaceuticalmarkets) Mon, 01 Oct 2007 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1044 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1044 Immunogenicity, the body's response to therapeutic proteins, is vitally important in the development and marketing of biotech drugs. Failure to predict and monitor levels of immunogenicity can have disastrous results for patients and for companies. (pharmaceuticalmarkets) Fri, 19 Oct 2007 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1045 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1045 A detailed guide to the factors that will shape this vital market, including company strategies, comparability, regulation, the implications for clinical trials and legal issues. With a chapter written by PWC looking at the commercial implications for the biotech and pharmaceutical markets (pharmaceuticalmarkets) Tue, 28 Nov 2006 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1046 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1046 Cardiac Toxicity - drugs causing heart muscle, valve damage or potentially fatal arrhythmias in patients - has been implicated in 28% of drug withdrawals in the USA over the last 30 years. The significance for patients, regulators and the pharmaceutical industry is immense. If cardiac toxicity is discovered during a drug’s development the programme will, almost invariably, be terminated. If cardiac toxicity is discovered after launch then the drug may be withdrawn or new labelling will almost certainly be required. (pharmaceuticalmarkets) Sun, 28 Mar 2004 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1047 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1047 Mid-sized Pharma companies are now much more successful than their bigger rivals - they are growing faster, are more profitable and are performing much better on the world's stock markets. The reasons behind that success are key to a full understanding of the pharmaceutical industry - and to its future growth. (pharmaceuticalmarkets) Fri, 23 May 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1052 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1052 The contract research market is booming, growing by 28% last year - far faster than the industry it serves. This review provides a complete picture of the market, looks at trends and developments and explains how they will affect the future of the market. And it includes details of more than 50 mergers, acquisitions and joint ventures. (pharmaceuticalmarkets) Tue, 24 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1053 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1053 Mega mergers and the blockbuster model have not delivered the benefits that were claimed for them - growth in the pharmaceutical market has slowed to no more than five per cent and the world's biggest companies are growing slowly, if at all. Against that background pharmaceutical companies, large and small, are looking for new ways to do business - ways that will bring success in a difficult market. For ways to discover and deliver new drugs, to manufacture them more cost-effectively and to sell and market them more successfully. (Dr John MacDonald) Wed, 10 Sep 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1054 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1054 Biologic drugs are complicated biological products that are normally difficult to define in molecular terms and that can be inconsistent in their exact composition. This can make it difficult to assure product quality and therefore to ensure safety and efficacy. There is no perfect solution and the commercial cost of quality is high, but can the cost of getting it wrong be considerably greater or even disastrous. Considerable time and expense can be saved by having an educated approach to manufacturing and process development, characterisation and analytical methods, product variation and also to regulatory issues. This unique new report provides a detailed and complete guide to the processes and methods involved. (pharmaceuticalmarkets) Tue, 09 Dec 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1055 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1055 This report analyzes the demand and supply, brand competition and trends of China's condom market. It's helpful to those who want to know and capture the China's condom market. In 2008, there were about 370 million women of child-bearing age in China. Because of family planning and other reasons, many of them need to be put on birth control. At present, more than 200 million married couples of childbearing age in China have adopted contraceptive measures… (Mathew. Teng) Mon, 05 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1056 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1056 The medical organizations in China belong to service industry, directly faced to numerous consumers and supervised by medical executive departments of Chinese government. The regional distributions of Chinese hygiene resources are comparatively balanced, regional distribution disparity mainly showing in the levels of medical organizations, asset scales, revenues and expenditures, private medical organization distribution and foreign funded medical distribution, reflecting the regional economic development differences. Chinese medical industry is mainly concentrated in Shanghai, Beijing, Guangdong and Zhejiang, accounting for most hygiene resources and higher level technologies. (Thomas. Woo) Mon, 23 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1057 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1057 With the deterioration of natural environment and the bad eating habits, there is an increasing number in Chinese malignant tumor patients. At present, the outbreak rate of Chinese male malignant tumor is 130.3 to 305.4 per one hundred thousand, and female of 39.5 to 248.7 per one hundred thousand. In 2008, the new cancer case loads in China exceeded 2.2 million and over 1.6 million deaths. In recent years, one in every four to five deaths is died of cancer, the leading cause of death. It is predicted that there will be 5.5 million new cancer case loads in 2020 in China and the deaths will reach to four million. (Thomas. Woo) Mon, 23 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1058 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1058 The chemical pharmaceuticals industry is the largest sub-sector of Chinese pharmaceuticals industry. In 2008, the sales revenues of Chinese chemical raw material medicines were 26.5 billion USD and the sales revenues of the chemical preparation industry were 3.34 billion USD, with the average growth rate all exceeding 20%. In 2008, China produced 2.2853 million tons chemical raw material medicines accumulatively, YOY up by 0.85% with the growth rate down by 15.05% compared with the same period of last year. (Bruce.Chang) Mon, 13 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1059 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1059 In 2008, the medical wholesale enterprises in Chinese medical circulation industry were about 12 thousand in small scale. Only about 5 hundred exceeded the annual sales amounts of 50 million Yuan (7.1 million USD). The top three medical circulation enterprises accounted for 20% market shares of the total medical sales amounts. In the mature market, the medical industry was highly concentrated. The top three American medical circulation enterprises accounted for 90% market shares and 70% in Japan. (Rati. Lee) Tue, 28 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1060 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1060 Zoonosis refers to a kind of infectious disease that plagues between animals and human beings. Some plagues, though discovered, spread widely all over the world. Others are newly found, such as the swine flu. (Jimmy.Wong) Tue, 28 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1061 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1061 The medicine terminals refer to the places where the consumers face the medicines directly, realize the exchange between currencies and medicines and the last step for the medicines to circulate from the manufacturers to the consumers. Among the various circulation steps, the medicine terminals are the place for the manufacturers to realize the medicine sales. (Rati. Lee) Mon, 18 May 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1062 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1062 In a fast-changing pharmaceutical market it is vital to be able to measure company performance easily and accurately – find out which companies are winning in the areas that count and which are suffering in changing circumstances. The new EvaluatePharma® Yearbook gives you the information that you need, in context. (pharmaceuticalmarkets) Tue, 22 Jul 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1063 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1063 Growth in the pharmaceutical market has slowed - almost to a standstill. One reason is that governments and other payers are cutting costs in a faltering world economy. But a more fundamental problem is the failure of major companies to discover, develop and market new drugs. Major drugs losing patent protection or being withdrawn from the market are simply not being replaced by new therapies - the pharmaceutical market model is no longer functioning effectively and most pharmaceutical companies are failing to produce the innovation needed for success. (pharmaceuticalmarkets) Wed, 08 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1064 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1064 The widely-acclaimed Complete Directory for People with Disabilities is an invaluable resource for all those committed to empowering individuals with disabilities. All those with a disability, from vision problems to physical disabilities to asthma, will find ways in this Directory to succeed at work, in school, and in their community. (pharmaceuticalmarkets) Fri, 01 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1066 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1066 This new second edition compares all of the nation's hospitals by 24 measures of quality in the treatment of heart attack, heart failure, pneumonia, and, new to this edition, surgical procedures and pregnancy care. Plus, this second edition is now available in regional volumes, to make locating information about hospitals in your area quicker and easier than ever before. (pharmaceuticalmarkets) Wed, 01 Aug 2007 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1067 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1067 This comprehensive, up-to-date directory provides parents and caregivers with comprehensive and useful information about common Pediatric Conditions, Disorders, Diseases and Disabilities. (pharmaceuticalmarkets) Fri, 01 May 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1068 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1068 This directory provides a comprehensive overview of the support services and information resources available for people diagnosed with a chronic illness. It details the wide range of organizations, educational materials, books, newsletters, web sites, periodicals and databases that address 88 specific chronic illnesses. (pharmaceuticalmarkets) Wed, 01 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1069 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1069 This sixth edition has been broadly expanded to offer the most comprehensive information covering the field of behavioral health, with detailed, comprehensive and critical information for not only those challenged with a mental disorder, their family and support network, but also for paraprofessionals and professionals in the field. (pharmaceuticalmarkets) Sat, 01 Mar 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1070 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1070 This comprehensive directory profiles over 800 Purchasing Organizations that negotiate more than 65% of all health care products purchased by hospitals and related facilities, and the institutions they represent. Listings include not only Group Purchasing Organizations, but also other types of Organizations that make volume health care purchases including: Multi-Hospital and Multi-Nursing Home Corporations; Alliances; Provider Management Companies; Physicians Offices; and Integrated Delivery Networks. (pharmaceuticalmarkets) Tue, 01 Jan 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1071 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1071 The Directory of Hospital Personnel is the best resource you can have at your fingertips when marketing a product or service to the hospital market. A "Who's Who" of the hospital universe, The Directory of Hospital Personnel puts you in touch with over 100,000 key decision makers. With the most up-to-date and comprehensive data at your fingertips, you can rest assured that you will reach the right person with just one call. Whether you're trying to find a group of hospitals fitting your profile or trying to find one individual, the answers you need are in this directory. (pharmaceuticalmarkets) Sun, 01 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1072 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1072 This comprehensive and up-to-date directory pulls together a vast array of contact information for over 8,000 Ambulatory Surgery Centers, Diagnostic Imaging Centers and Freestanding Urgent Care Centers. (pharmaceuticalmarkets) Wed, 01 May 2002 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1073 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1073 This directory is the first-ever resource to bring together, all in one place, data on the many drug and alcohol residential rehabilitation facilities in the United States. (pharmaceuticalmarkets) Wed, 01 Oct 2003 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1074 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1074 The HMO/PPO Directory is a comprehensive source that provides detailed information about Health Maintenance Organizations and Preferred Provider Organizations nationwide, including key contacts. This edition details more information about more managed healthcare organizations than ever before. (pharmaceuticalmarkets) Wed, 01 Oct 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1075 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1075 The only one-stop resource of every medical supplier licensed to sell products in the US. This edition offers fast access to over 13,000 companies - and more than 65,000 products. This comprehensive resource saves you hours of time and trouble when searching for the equipment and supplies you want and the manufacturers who provide them. (pharmaceuticalmarkets) Mon, 01 Dec 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1076 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1076 Older Americans Information Directory is an invaluable resource that offers up-to-date information on the prevalent social, health and financial issues facing older Americans in the 21st century, as well as recreational and educational opportunities to enrich their lives. (pharmaceuticalmarkets) Sat, 01 Mar 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1077 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1077 China's pharmaceutical market is not only a large, rising opportunity in itself - reaching an estimated $37 billion in 2008 and still growing at near 20% annually - in the near future, it will also join the world's biggest pharmaceutical markets. This makes it strategically crucial for Western pharmaceutical companies to succeed there. However, the Chinese drug market has unique characteristics which must be understood to make the China potential a reality. (Arnes Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1078 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1078 This report includes a brief overview of the pharmaceutical and healthcare industry in China, as well as a discussion of all the relevant laws and regulations that govern the testing, registration, manufacture, import, marketing, and sale of pharmaceutical products. Specific topics include: product registration, pricing and reimbursement, importation, GMP, GCP, orphan drugs, and intellectual property protection. (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1079 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1079 This report on Asian CROs provides a comprehensive list of clinical research organizations throughout Asia. The countries covered include: Japan, Taiwan, Korea, Singapore, Hong Kong, India, China, Malaysia, Philippines, Indonesia and Thailand. Included for each CRO is the contact information, description of services and comments about the CRO. (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1080 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1080 The India Pharmaceutical Regulatory Report comprehensively covers all aspects of pharmaceutical regulations in India. It includes overviews of the laws and procedures on registration, manufacturing, distribution, price control, marketing, research and development, and intellectual property protection. It also includes an overview of the Indian pharmaceutical market and foreign involvement in the market up to 2009. (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1081 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1081 Recently, Western medical device manufacturers have had to comply with Japan's Quality Management System (QMS) standards to register and sell their products in Japan. Pacific Bridge Medical's new report is the only comprehensive English guide to the new Japanese quality audits, including official quality system requirements, documents needed, tips for success, and translations of key Japanese regulations. (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1082 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1082 Following the example of the US FDA's Orphan Drug Act established in 1983, some Asian nations have developed orphan drug legislation, such as Singapore's Orphan Drug Exemption to the Medicines Act and Japan's Orphan Drug Amendment to the Pharmaceutical Affairs Law. While orphan drug laws in Asia may provide benefits for companies registering new drugs, such as marketing exclusivity, an expedited registration process, and a reduction in the number of clinical trials required, each registration process is unique and can pose a variety of challenges (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1083 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1083 Sourcing manufactured goods in Asia has become common as more and more companies take advantage of the lower overhead, lower labor costs, and increasing technical capabilities available in Asia. Medical device companies can buy and manufacture a wide array of components and medical devices from Asia at significantly lower cost and relatively high quality. (By Ames Gross and John Minot) Thu, 01 Jan 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1099 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1099 As regulatory frameworks for biosimilars development begin to take shape worldwide, there are growing opportunities for generics companies to enter the biologics market, a segment which is uniquely driven by unmet needs, commands premium prices, and continues to outperform the global pharma market. (pharmaceuticalmarkets) Thu, 09 Jul 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1100 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1100 The main application of apoptosis research is presently in cancer treatment. It should be noted that this market is one of the largest and fastest growing sectors of the pharma industry. Of the 370 pipeline agents identified in Apoptosis 2009: Opportunities in Cancer and Other Diseases, 80% are anticancers. (pharmaceuticalmarkets) Sun, 01 Feb 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1109 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1109 Dyslipidemia: Opportunities in Cardiovascular Risk Reduction is a 200-page comprehensive and insightful study of scientific and commercial trends and opportunities in the worldwide lipid-modulating market, which is poised for transformation with the advent of novel combination products and biopharmaceuticals. (pharmaceuticalmarkets) Fri, 01 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1173 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1173 President Barack Obama said during his election campaign he would 'allow Americans to buy their medicines from other developed countries if the drugs are safe and prices are lower outside the US'. He began delivering on this promise with a fiscal 2010 budget request for funds ‘to allow the FDA to begin developing policies for drug importation’. (Donald Macarthur) Mon, 01 Jun 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1174 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1174 In an otherwise volatile pharmaceutical world, 2009 has seen two notable and durable anniversaries, the implementation of the tenth re-negotiated Pharmaceutical Price Regulation Scheme in January and the tenth birthday of the National Institute for Health and Clinical Excellence in April. PPRS and NICE, are among abbreviations most widely recognised, but their structures, functions and ways of working are often less than fully understood. (Donald Macarthur) Wed, 01 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1175 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1175 Very little in the pricing environment in Europe is predictable to pharmaceutical companies and only rarely is much notice given of change. But before the end of 2009, if the European Court of Justice accepts the arguments put to it forcefully by the European Commission and by DocMorris, then revolutionary reform among industry’s main customer group, the community pharmacist, in several of the main countries, including 4 of the EU-5, will get the green light. (Donald Macarthur) Mon, 01 Sep 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1176 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1176 Public hospitals represent a very important market segment for most biopharmaceutical companies in Europe. They are the often the only market for the increasing numbers of speciality products emerging from R&D, with many primary care products also unable to get established for maintenance therapy in the community without hospital recommendation first. (Donald Macarthur) Fri, 01 Aug 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1177 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1177 No serious multinational can afford to ignore Japan, but it remains a tough and highly competitive market to crack, with the environment for developing and marketing medicines dominated by price. Virtually no new prescription brand can be introduced without a yakka (reimbursement price) set by the government. (Donald Macarthur) Sun, 01 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1178 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1178 In order to raise public awareness, 29 February 2008 was dedicated the first European rare disease day ('a rare day for very special people'), but European payers need no reminding of the significance of rare disease treatments, generally known as orphan drugs. (Donald Macarthur) Tue, 01 Apr 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1528 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1528 This report is meant for IT vendors and intends to help them identify selling opportunities within the company. Further, the identified sales drivers can be used to penetrate these accounts or increase current share of the customer's wallet. (pharmaceuticalmarkets) Fri, 13 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1529 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1529 Fresenius SE is a Germany-based holding company of the Fresenius Group, operating in the healthcare sector, with products and services for dialysis, hospitals and outpatient medical care. The Group also offers engineering and services for hospitals and other healthcare facilities. (pharmaceuticalmarkets) Fri, 20 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1530 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1530 Laboratory Corporation of America Holdings (LabCorp) is an independent clinical laboratory company in the United States. The company has a national network of 37 primary laboratories and over 1,600 patient service centers along with a network of branches and STAT laboratories, which are laboratories that have the ability to perform certain routine tests and report the results to the physician immediately. (pharmaceuticalmarkets) Fri, 20 Jun 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1531 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1531 Pfizer Inc. is a pharmaceutical company founded in 1849, Pfizer's key areas of business include pharmaceutical products, consumer health care products and animal health products. It works in partnership with governments, individuals and other payers for healthcare to treat and prevent illnesses. (pharmaceuticalmarkets) Mon, 03 Nov 2008 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1532 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1532 Located in the US, Mayo Clinic Rochester (Mayo Clinic) is a subsidiary of Mayo foundation. Mayo Clinic Rochester includes Mayo Clinic, Saint Marys Hospital, Mayo Eugenio Litta Children's Hospital, and Rochester Methodist Hospital. Mayo Clinic conducts medical tests, diagnosis, and treatments along with clinical and research laboratory operations. (pharmaceuticalmarkets) Thu, 26 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1533 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1533 Headquartered in Mumbai, Wockhardt Limited is an India based pharmaceutical company. It is a subsidiary of Khorakiwala Holdings and Investments Private Limited. In addition to India, the company also has its operations in the United States, Western Europe, and in other parts of the world. (pharmaceuticalmarkets) Thu, 26 Mar 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1534 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1534 Headquartered in the United States, Abbott Laboratories deals in discovery, development, manufacture, and sales of healthcare products. The company has four business segments as Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Vascular Products. (pharmaceuticalmarkets) Wed, 08 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1535 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1535 Providing services such as hospital services, pharmaceutical services, and consulting services, Apollo Hospitals Enterprises Limited (Apollo Hospitals) is an integrated healthcare company. (pharmaceuticalmarkets) Wed, 08 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1536 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1536 Fortis Healthcare Limited is a healthcare subsidiary of Ranbaxy India Private limited. The company operates and manages a chain of multi-speciality hospitals. (pharmaceuticalmarkets) Wed, 08 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1537 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1537 Headquartered in Delhi, Max India Limited is an India based company. The company has two main segments of operation as Business Investments and speciality Plastic products. The business investment segment has operations in a wide range of industry verticals including insurance, healthcare, clinical research, and healthcare staffing business along with treasury investments. (pharmaceuticalmarkets) Wed, 08 Apr 2009 00:00:00 GMT http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1538 http://www.pharmaceuticalmarkets.com/Report.aspx?rid=1538 Cigna Corporation (Cigna) is a US-based health services organization, headquartered in Philadelphia. The company, along with its subsidiaries, provides healthcare products & services, group disability, life insurance, accident insurance, and compensation case management services. (pharmaceuticalmarkets) Mon, 11 May 2009 00:00:00 GMT